Table 3.
Functional Pathways Identified Both in the Analysis of the Predicted Targets of miRNAs in Exosomes that Were Less in Syndecan-1–Deficient Conditions and in the Analysis of Genes Up-Regulated in Adenocarcinoma Samples
| KEGG pathway | FDR |
|---|---|
| Cell cycle | 9.64 × 10−19 |
| p53 signaling pathway | 7.87 × 10−6 |
| Oocyte meiosis | 1.19 × 10−5 |
| Bladder cancer | 5.24 × 10−5 |
| RNA transport | 1 × 10−4 |
| Melanoma | 1.8 × 10−3 |
| Glioma | 2.8 × 10−3 |
| Pancreatic cancer | 5.1 × 10−3 |
| Prostate cancer | 1.2 × 10−2 |
| Chronic myeloid leukemia | 1.7 × 10−2 |
| Non–small cell lung cancer | 1.8 × 10−2 |
| ErbB-signaling pathway | 2.2 × 10−2 |
| Neurotrophin-signaling pathway | 3.2 × 10−2 |
| Endometrial cancer | 3.7 × 10−2 |
| Lysine degradation | 4.5 × 10−2 |
ErbB, epidermal growth factor receptor; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes.